Critical limb ischemia is a severe form of peripheral artery disease wherein reduced blood flow in the leg arteries causes pain and discomfort. The commonly used treatment options for critical limb ischemia include drugs, endovascular therapy, and surgeries. Endovascular therapies involve minimally invasive procedures such as balloon angioplasty and intravascular stent placement to restore blood flow in diseased arteries. The rising preference for endovascular therapies over invasive surgeries owing to its benefits such as faster recovery and lower risk of complications has been fueling the demand for associated devices and technologies.
The global critical limb ischemia treatment market is estimated to be valued at USD 5.10 Bn in 2024 and is expected to reach USD 9.11 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.6% from 2024 to 2031.
Key Takeaways
Key players operating in the critical limb ischemia treatment are Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Cook Medical Inc., Cardiovascular Systems, Inc., Philips Healthcare, B. Braun Melsungen AG, Terumo Corporation, Biotronik SE & Co. KG, Cordis Corporation, Smith & Nephew plc, Stryker Corporation, AngioDynamics, Inc., GE Healthcare, Sanofi S.A., AstraZeneca plc, and Bristol-Myers Squibb Company. The key players are focused on developing advanced endovascular devices and drugs to gain a competitive advantage.
The growing demand for minimally invasive treatments along with rising geriatric population suffering from peripheral vascular diseases are expected to create significant growth opportunities for players in the critical limb ischemia treatment market. Furthermore, technological advancements in the field of endovascular therapies such as drug-eluting stents and arteriovenous fistula devices are likely to drive the adoption of treatment options for critical limb ischemia.
High unmet needs, rising healthcare expenditure, and increasing FDA approvals are expected to drive the critical limb ischemia treatment market. The growing geriatric population is more prone to develop peripheral arterial diseases owing to reduced blood circulation, aging arteries, and other comorbidities like diabetes and hypertension, which increases the risk of critical limb ischemia. This makes aging demography a major growth driver for this market.
Market Drivers
The rising geriatric population is one of the key drivers propelling the growth of Critical Limb Ischemia Treatment Market Share. People aged above 60 years exhibit a significantly higher prevalence rate of peripheral arterial diseases when compared to other age groups. According to the United Nations Population Fund (UNFPA), the population aged 60 years and above is growing at a faster rate relative to all other age groups. Since aging adversely influences circulation, it further increases the chances of developing critical ischemia in legs. As per estimates, over 1.4 billion people are projected to be aged 60 years and above globally by the end of 2040. This rising pool of geriatrics is directly proportional to the growing demand for advanced and effective therapies for critical limb ischemia.
Current Challenges in Critical Limb Ischemia Treatment Market
The critical limb ischemia treatment market faces a few challenges currently. Firstly, there is a lack of awareness about the condition of critical limb ischemia amongst both patients and physicians. As the condition progresses slowly, symptoms are often ignored in the initial stages. By the time a diagnosis is made, the condition has advanced significantly. Secondly, treatment options like revascularization surgeries are highly complex and expensive. Not all patients can afford or have access to such advanced treatment procedures. This hampers effective management of critical limb ischemia. Lastly, long-term outcomes of current treatment strategies need improvement. Amputation rates continue to remain high indicating the need for more effective therapeutic options. Overall, overcoming barriers to early diagnosis and improving long-term outcomes post-treatment are the major challenges facing this market currently.
SWOT Analysis
Strength: Advancements in minimally invasive treatment devices like drug-coated balloon catheters, stent grafts and atherectomy devices improve revascularization success rates and reduce complications.
Weakness: High treatment costs put therapies out of reach for many patients in developing regions.
Opportunity: Increasing incidence of diabetes, a primary risk factor, and growth of elderly population create a large untapped market potential.
Threats: Long development cycles and regulatory approval delays hamper timely market entry of novel treatment innovation.
Geographical Regions
North America currently accounts for the largest share of the Critical Limb Ischemia Treatment Market In Size, valued at over US$ 3 Bn in 2024. High healthcare expenditure and availability of advanced therapies drive this region's dominance. The Asia Pacific region is projected to grow at the fastest pace during the forecast period, fueled by China and India's rapidly developing healthcare industries and growing disease burden. Economic development in these populous nations will expand patient access to treatment over time.
The geographical region which is currently growing the fastest in the critical limb ischemia treatment market is Asia Pacific. The rising incidence of diabetes and peripheral artery disease, coupled with improving healthcare infrastructure and diagnostic capabilities, is driving robust growth in this region. China and India specifically offer immense untapped market potential with their huge patient populations and increasing focus on noncommunicable diseases. As healthcare spending increases across Asia Pacific, more patients will be able to access critical limb ischemia treatments, propelling the market forward in the coming years.
Get more insights on Critical Limb Ischemia Treatment Market
For Deeper Insights, Find the Report in the Language that You want
About Author
Alice Mutum, is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.
(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )
copyright src="chrome-extension://fpjppnhnpnknbenelmbnidjbolhandnf/content_script_web_accessible/ecp_aggressive.js" type="text/javascript">